Switch Therapeutics
Maxine Nelson, PhD, is a Senior Scientist at Switch Therapeutics, specializing in neuroscience with a focus on developing in vitro models and collaborating with various departments to enhance the Neuroscience portfolio. Previously, as a PhD Candidate at the University of California, San Francisco, Maxine conducted significant research on gene editing and Alzheimer’s disease, contributing to advancements in understanding protective genetic mutations. Early career experiences include roles as Adjunct Faculty Instructor, Co-Founder of The STEM Chicks, and Research Associate at ADRx, Inc., where Maxine combined scientific research with educational outreach and graphic design. Maxine holds a PhD in Biomedical Sciences from UCSF and a Bachelor's Degree in Bioengineering and Multimedia from California Lutheran University.
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.